biostudies-literatureUnknown11(2)Liu Q<h4>Background</h4>Although poly (ADP-ribose) polymerase inhibitors (PARPis) have transformed the treatment landscape for the BReast CAncer susceptibility gene (BRCA)-mutated ovarian cancer, emerging evidence suggests significant heterogeneity in treatment efficacy. However, findings regarding the impact of mutation location and type remain debated, underscoring the necessity for more data and better subclassification. This study aimed to evaluate the association between novel BRCA mutation subgroups and PARPi response in epithelial ovarian cancer.<h4>Patients and methods</h4>This is a multicenter retrospective study conducted in China which enrolled BRCA1/2-mutated epithelial ovarian cancer patients between 2015 and 2024. Patients who achieved complete or partial response after surgery anESMO open106060https://www.ebi.ac.uk/biostudies/studies/S-EPMC12874307biostudies-literatureA novel BRCA mutation classification system reveals differential responses to PARP inhibition and prognostic outcomes in epithelial ovarian cancer: a multicenter study.PMC12874307Huang CWu MTao LFan YLiu QJin YSong JYang XLiu YLi YWang SZhang YGuo HHuang XCui ZZhao DQiao JHa CKong WfalseA novel BRCA mutation classification system reveals differential responses to PARP inhibition and prognostic outcomes in epithelial ovarian cancer: a multicenter study.<h4>Background</h4>Although poly (ADP-ribose) polymerase inhibitors (PARPis) have transformed the treatment landscape for the BReast CAncer susceptibility gene (BRCA)-mutated ovarian cancer, emerging evidence suggests significant heterogeneity in treatment efficacy. However, findings regarding the impact of mutation location and type remain debated, underscoring the necessity for more data and better subclassification. This study aimed to evaluate the association between novel BRCA mutation subgroups and PARPi response in epithelial ovarian cancer.<h4>Patients and methods</h4>This is a multicenter retrospective study conducted in China which enrolled BRCA1/2-mutated epithelial ovarian cancer patients between 2015 and 2024. Patients who achieved complete or partial response after surgery an2026-01-01T00:00:00Z2026 Jan2026-07-15T06:59:27.991Z2026-06-30T03:35:49.347ZS-EPMC128743074161638910.1016/j.esmoop.2026.106060